These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 20364125)

  • 21. Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia.
    Thompson KP; Sykes J; Chandakkar P; Marambaud P; Vozoris NT; Marchuk DA; Faughnan ME
    Orphanet J Rare Dis; 2022 Nov; 17(1):405. PubMed ID: 36344987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pericytes as targets in hereditary hemorrhagic telangiectasia.
    Thalgott J; Dos-Santos-Luis D; Lebrin F
    Front Genet; 2015; 6():37. PubMed ID: 25763012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding.
    Beckman JD; Li Q; Hester ST; Leitner O; Smith KL; Kasthuri RS
    Orphanet J Rare Dis; 2020 Jul; 15(1):185. PubMed ID: 32660636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pericytes in Hereditary Hemorrhagic Telangiectasia.
    Galaris G; Thalgott JH; Lebrin FPG
    Adv Exp Med Biol; 2019; 1147():215-246. PubMed ID: 31147880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Practice Guideline: Nosebleed (Epistaxis).
    Tunkel DE; Anne S; Payne SC; Ishman SL; Rosenfeld RM; Abramson PJ; Alikhaani JD; Benoit MM; Bercovitz RS; Brown MD; Chernobilsky B; Feldstein DA; Hackell JM; Holbrook EH; Holdsworth SM; Lin KW; Lind MM; Poetker DM; Riley CA; Schneider JS; Seidman MD; Vadlamudi V; Valdez TA; Nnacheta LC; Monjur TM
    Otolaryngol Head Neck Surg; 2020 Jan; 162(1_suppl):S1-S38. PubMed ID: 31910111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Gene Analysis of A Chinese Family with Hereditary Hemorrhagic Telangiectasia and its Curative Effect of Thalidomide].
    Yu Q; Cheng Z; Yi YF; Peng HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1136-1141. PubMed ID: 28823282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic Diagnosis of Hereditary Hemorrhagic Telangiectasia: Four Novel Pathogenic Variations in Turkish Patients.
    Baysal M; Demir S; Ümit EG; Gürkan H; Baş V; Karaman Gülsaran S; Demirci U; Kırkızlar HO; Demir AM
    Balkan Med J; 2019 Dec; 37(1):43-46. PubMed ID: 31594285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia.
    Wang XY; Chen Y; Du Q
    Eur Rev Med Pharmacol Sci; 2013 Apr; 17(8):1114-6. PubMed ID: 23661527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT).
    Zarrabeitia R; Albiñana V; Salcedo M; Señaris-Gonzalez B; Fernandez-Forcelledo JL; Botella LM
    Curr Vasc Pharmacol; 2010 Jul; 8(4):473-81. PubMed ID: 19485912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options.
    Flanagan BA; Collins C; Parra S
    Cutis; 2012 Feb; 89(2):69-72. PubMed ID: 22474728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced mural cell coverage and impaired vessel integrity after angiogenic stimulation in the Alk1-deficient brain.
    Chen W; Guo Y; Walker EJ; Shen F; Jun K; Oh SP; Degos V; Lawton MT; Tihan T; Davalos D; Akassoglou K; Nelson J; Pile-Spellman J; Su H; Young WL
    Arterioscler Thromb Vasc Biol; 2013 Feb; 33(2):305-10. PubMed ID: 23241407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Research progress of bevacizumab in the treatment of refractory epistaxis caused by hereditary hemorrhagic telangiectasia].
    Xu C; Wang HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jun; 51(6):476-9. PubMed ID: 27345893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia.
    Shovlin CL; Millar CM; Droege F; Kjeldsen A; Manfredi G; Suppressa P; Ugolini S; Coote N; Fialla AD; Geisthoff U; Lenato GM; Mager HJ; Pagella F; Post MC; Sabbà C; Sure U; Torring PM; Dupuis-Girod S; Buscarini E;
    Orphanet J Rare Dis; 2019 Aug; 14(1):210. PubMed ID: 31462308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial.
    Dupuis-Girod S; Pitiot V; Bergerot C; Fargeton AE; Beaudoin M; Decullier E; Bréant V; Colombet B; Philouze P; Faure F; Letievant JC
    Sci Rep; 2019 Aug; 9(1):11986. PubMed ID: 31427745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia.
    Ruiz-Llorente L; Gallardo-Vara E; Rossi E; Smadja DM; Botella LM; Bernabeu C
    Expert Opin Ther Targets; 2017 Oct; 21(10):933-947. PubMed ID: 28796572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial.
    Yaniv E; Preis M; Shevro J; Nageris B; Hadar T
    Rhinology; 2011 Jun; 49(2):214-6. PubMed ID: 21743879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Future treatments for hereditary hemorrhagic telangiectasia.
    Robert F; Desroches-Castan A; Bailly S; Dupuis-Girod S; Feige JJ
    Orphanet J Rare Dis; 2020 Jan; 15(1):4. PubMed ID: 31910860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia.
    Simonds J; Miller F; Mandel J; Davidson TM
    Laryngoscope; 2009 May; 119(5):988-92. PubMed ID: 19194865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia.
    Colombo G; Bortolotti F; Chiapponi V; Buttini F; Sonvico F; Invernizzi R; Quaglia F; Danesino C; Pagella F; Russo P; Bettini R; Colombo P; Rossi A
    Int J Pharm; 2016 Nov; 514(1):229-237. PubMed ID: 27863666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
    Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
    Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.